This sounds very optimistic!!

Patients who take apabetalone have fewer heart attacks, strokes and cardiac-related deaths. Our data has also shown that a whole host of proteins associated with chronic kidney disease are normalized after treatment with apabetalone. The following diagram describes the overlapping, biological processes underlying the development of cardiovascular disease and how apabetalone and the inhibition of BET proteins can reduce the incidence of MACE. A BRIGHT FUTURE As apabetalone can be administered as a twice daily tablet, it will be affordable and easy to take for all our patients. Most importantly, apabetalone has proven to be safe. Due to its unique epigenetic mechanism, we continue to discover more ways that apabetalone can benefit patients across a broader range of chronic diseases, including neurodegenerative diseases, peripheral artery disease and a number of rare diseases.